

CENTER FOR DRUG EVALUATION AND RESEARCH

**APPLICATION NUMBER:
22-509**

**CLINICAL PHARMACOLOGY AND
BIOPHARMACEUTICS REVIEW(S)**

REV-CLINPHARM-02 (Review Noted (NAI))

NDA-022509

ORIG-1

Supporting Document 1

NEW/NDA

Submit Date: 03/31/2009 - FDA Received Date: 03/31/2009

The OCP information was withdrawn from this NDA and resubmitted as part of the supplement (NDA 22-115) under the other NDA.

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-22509	ORIG-1	SMITHKLINE BEECHAM CORP DBA GLAXOSMITHKLIN E	LAMICTAL XR(LAMOTRIGINE)ORAL TABLETS

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

TA-CHEN WU

01/28/2010

The OCP information was withdrawn from this NDA and resubmitted as part of the supplement (NDA 22-115) under the other NDA.

YUXIN MEN

02/02/2010